There have been significant advancements in the area of gene therapy in terms of research of new drugs. Over the past 20 years, the gene therapy market has witnessed significant advances ranging from the stage of conception, to the current stage of clinical trials for various disease conditions. When compared to other conventional methods such as radiotherapy and chemotherapy, gene therapy enjoys a clear advantage mainly because this therapy does not inhibit the immune system. Also, there has been an increased use of innovative technologies, which has led to an expansion of the scope of gene therapy worldwide. With continuous growth in this market along with major research and developments breakthroughs, the global market opportunity for gene therapy is expected to reach USD 500 million by 2020.

There are only 2 gene therapies which have been approved till now. They are Gendicine and Rexin-G. While Gendicine is marketed in China, Rexin-G is marketed in Philippines. China, with its significant efforts in researching gene therapy has become the first country to approve gene therapy products across the globe in 2003. The growing need for developing an effective treatment for head-and-neck cancer, a condition more prevalent in China than in the west, sustained the interest among Chinese researchers in this area. The market for gene therapy is currently in the experimental stages. There has not been any success as yet in developing completely curative therapeutic drugs.

The growth of this market greatly depends on the regulatory approval of products which are currently in clinical trials. A major part of the gene therapy products for cancer and cardiovascular diseases are currently in Phase II and Phase III of clinical trials. Other factors impacting the gene therapy market are the cost of the treatment and the disease population under study. Additionally, funding and developments in research coupled with acceptance of gene therapy products to use in medicine are also expected to impact the market in the near future.

Although the initial studies of gene therapy were conducted mostly on monogenetic diseases, the focus of the scientists rapidly shifted towards cancer. This increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for dominant share in the overall clinical trials being conducted. The major reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer.

"Global Gene Therapy Market & Pipeline Insight" Market Highlight:

- Gene Therapy Market Overview
- Significance of Gene Therapy in Cancer Therapeutics
- Current Applications of Gene Therapy to Cancer Treatment
- Gene Therapy Market Dynamics: Drivers, Challenges & Future Outlook
- FDA & AMA Guidelines for Gene Therapy
- Gene Therapy Pipeline by Phase, Indications, Country & Company
- Gene Therapy Pipeline: 246 Drugs
- Marketed Gene Therapy: 2 (Gendicine & Rexin-G)
- Cancer Gene Therapy Pipeline: 69 Drugs

Contents:

1. Introduction to Gene Therapy
   1.1 History of Gene Therapy
   1.2 Vectors of Gene Therapy
      1.2.1 Viral Vectors
      1.2.2 Non-Viral Vectors
   1.3 Gene Therapy Protocol

2. Gene Therapy Classification
   2.1 Somatic Gene Therapy
      2.1.1 Technique of Somatic Gene Therapy
2.2 Germline Cell Therapy
  2.2.1 Technique of Germline Therapy

3. Mechanism of Gene Therapy
  3.1 Approach of Gene Therapy
  3.2 Mechanism of Genetic Manipulation

4. Global Gene Therapy Market Overview
  4.1 Current Market Scenario
  4.2 Gene Therapy Clinical Pipeline Overview
  4.3 Emerging Trends in Gene Therapy

5. Significance of Gene Therapy in Cancer Therapeutics

6. Current Applications of Gene Therapy to Cancer Treatment
  6.1 Cancer Treatments Currently Available
  6.2 Approaches to Cancer Gene Therapy
  6.3 Gene Therapy Used in Cancer Treatment
  6.4 Methods of Inserting Genes into Cancer Patients
  6.5 Cancer Gene Therapy Clinical Insight

7. Global Gene Therapy Market Dynamics
  7.1 Favorable Parameters
    7.1.1 Curing the Incurable Diseases
    7.1.2 Testing Technology
    7.1.3 Reimbursement Policy
    7.1.4 Rising Incidence of Cancer
    7.1.5 Increasing Investments
    7.1.6 Integration of Bioinformatics
  7.2 Growth Restraints

8. Gene Therapy Market Future Growth Outlook

9. EMA Guidelines for Gene Therapy
  9.1 Non Clinical Testing for Inadvertent Germline Transmission of Gene Transfer Vectors
  9.2 Scientific Requirements for the Environmental Risk Assessment of Gene Therapy Medicinal Products
  9.3 Risk Based Approach Applied to Advanced Therapy Medicinal Products
  9.4 Quality, Non Clinical & Clinical Aspects of Medicinal Products Containing Genetically Modified Cells
  9.5 Follow Up of Patients Administered with Gene Therapy Medicinal Products
  9.6 Non Clinical Studies Required Before First Clinical Use of Gene Therapy Medicinal Products

10. FDA Guidelines for Gene Therapy
    10.1 Preclinical Assessment of Investigational Cellular & Gene Therapy Products
    10.2 Potency Tests for Cellular & Gene Therapy Products
    10.3 Human Somatic Cell Therapy & Gene Therapy
    10.4 Gene Therapy Clinical Trials - Observing Subjects for Delayed Adverse Events

11. Gene Therapy Pipeline by Phase, Indications, Country & Company
    11.1 Unknown
    11.2 Research
    11.3 Preclinical
    11.4 Clinical
    11.5 Phase-I
    11.6 Phase-I/II
    11.7 Phase-II
    11.8 Phase-II/III
    11.9 Phase-III
    11.10 Preregistration
    11.11 Registered

12. Marketed Gene Therapies by Indications, Country & Company
    12.1 Gendicine (Shenzhen SiBiono GeneTech)
    12.2 Rexin-G (Epeius Biotechnologies)
13. Suspended & Discontinued Gene Therapy in Pipeline
13.1 No Development Reported
13.2 Discontinued
13.3 Suspended

14. Competitive Landscape
14.1 Advantagene
14.2 BioCancell
14.3 Celgene
14.4 Epeius Biotechnologies
14.5 GenVec
14.6 Genethon
14.7 Introgen Therapeutics
14.8 MultiVir
14.9 Shenzhen SiBiono GeneTech
14.10 Vical
14.11 ZIOPHARM Oncology

List of Tables:

Table 1-1: Approved Current Clinical Gene Therapy Protocols
Table 9-1: Classification of Integrating & Non-Integrating Vectors Based on the Parental Virus/Plasmid Characteristics
Table 9-2: Risk factors of GT Medicinal Products to be Considered
Table 10-1: Challenges to Potency Assay Development for CGT Products
Table 10-2: Commonly Used Gene Therapy Vectors in Clinical Trials

List of Figures:

Figure 1-1: Protocol for Human Gene Therapy Clinical Trials
Figure 2-1: Technique of Somatic Gene Therapy
Figure 2-2: Steps Involved in a Human Germline Gene Therapy Protocol
Figure 3-1: Genetic Modification of Organisms
Figure 4-1: Global Gene Therapy Market Opportunity (US$ Million), 2014-2020
Figure 4-2: Gene Therapy Clinical Pipeline by Phase (%), 2014
Figure 4-3: Gene Therapy Clinical Pipeline by Phase (Number), 2014
Figure 4-4: No Development Reported in Gene Therapy Clinical Pipeline by Phase (%), 2014
Figure 4-5: No Development Reported in Gene Therapy Clinical Pipeline by Phase (Number), 2014
Figure 4-6: Discontinued Gene Therapy Clinical Pipeline by Phase (%), 2014
Figure 4-7: Discontinued Gene Therapy Clinical Pipeline by Phase (Number), 2014
Figure 4-8: Suspended Gene Therapy Clinical Pipeline by Phase (%), 2014
Figure 4-9: Suspended Gene Therapy Clinical Pipeline by Phase (Number), 2014
Figure 6-1: Cancer Gene Therapy Drug Clinical Pipeline by Phase (%), 2014
Figure 6-2: Cancer Gene Therapy Drug Clinical Pipeline by Phase (Number), 2014
Figure 6-3: Suspended Cancer Gene Therapy Drug by Phase (%), 2014
Figure 6-4: Suspended Cancer Gene Therapy Drug by Phase (Number), 2014
Figure 6-5: Discontinued Cancer Gene Therapy Drug by Phase (%), 2014
Figure 6-6: Discontinued Cancer Gene Therapy Drug by Phase (Number), 2014
Figure 6-7: No Development Reported Cancer Gene Therapy Drug by Phase (%), 2014
Figure 6-8: No Development Reported Cancer Gene Therapy Drug by Phase (Number), 2014
Figure 14-1: Advantagene Clinical Pipeline
Figure 14-2: Genethon Clinical Pipeline
Figure 14-3: MultiVir Clinical Pipeline
Figure 14-4: Vical Clinical Pipeline
Figure 14-5: ZIOPHARM Oncology Clinical Pipeline

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Gene Therapy Market & Pipeline Insight
Web Address: http://www.researchandmarkets.com/reports/3006346/
Office Code: SCDK3BKX

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td>□</td>
<td>USD 2040</td>
</tr>
<tr>
<td>Single User</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>USD 2400 - Until 30th Apr 2016</td>
</tr>
<tr>
<td>CD-ROM</td>
<td>□</td>
<td>USD 2380 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td></td>
<td></td>
<td>USD 2800 - Until 30th Apr 2016</td>
</tr>
<tr>
<td>Hard Copy</td>
<td>□</td>
<td>USD 2805 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td></td>
<td></td>
<td>USD 3300 - Until 30th Apr 2016</td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td>□</td>
<td>USD 4080</td>
</tr>
<tr>
<td>Enterprisewide</td>
<td></td>
<td>USD 4800 - Until 30th Apr 2016</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ___________________________  Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Title:  
Fax Number:

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World